News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website

Oncolytics Biotech Inc. Announces 2004 Third Quarter Results

Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)


Posted on: 11/04/2004

Oncolytics Biotech Inc. Announces 2004 Third Quarter Results

CALGARY, Nov. 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced its financial results for the three and nine-month periods ending September 30, 2004. The current clinical program for REOLYSIN(R) includes a Phase I systemic administration trial in the United Kingdom, and a Phase I/II recurrent malignant glioblastoma trial in Canada. Enrolment is continuing as expected in the Phase I systemic administration trial at the Royal Marsden Hospital, and the Company added a second clinical site at St. George's Hospital in London.

The Company also announced a poster presentation at the 16th EORTC-NCI-AACR 2004 Symposium entitled "The oncolytic reovirus, REOLYSIN(R), augments the anticancer effects of cytotoxic agents in vitro against the ras-mutated human colon cancer cell line HCT 116." The data will be helpful in designing future clinical studies.

Oncolytics continues to prepare for the expected expansion of the human clinical program by working with manufacturing suppliers to ensure that supplies of REOLYSIN(R) are available.

"The Company continues to implement a step-wise approach to developing REOLYSIN(R) as a potential cancer therapeutic," said Dr. Brad Thompson, President and CEO of Oncolytics.

[Click on the link above for the remainder of this story - which just has financial news]

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557